Myrexis, Inc.
Records under this name other than the patents Myrexis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,595,401 | Therapeutic Compounds and Their Use in Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,476,285 | Purine-Core Inhibitors of HSP90 and Their Use in Treating Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,653,139 | Drug substance preparations, pharmaceutical compositions and dosage forms Formerly held Lapsed on the fee record Ended Feb 18, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 18, 2026 | From the USPTO record |
| US 8,318,425 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein Term ended Term ended Sep 11, 2024 · From the USPTO record | Term ended | Term ended Sep 11, 2024 | From the USPTO record |
| US 9,034,871 | Compounds for Alzheimer's disease Formerly held Lapsed on the fee record Ended May 19, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 19, 2023 | From the USPTO record |
| US 8,912,184 | Therapeutic and diagnostic methods Formerly held Lapsed on the fee record Ended Dec 16, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 16, 2022 | From the USPTO record |
| US 7,714,022 | Pyrrole derivatives as therapeutic compounds Formerly held Lapsed on the fee record Ended May 11, 2022 · From the USPTO record | Lapsed on the fee record | Ended May 11, 2022 | From the USPTO record |
| US 7,678,823 | Compounds for alzheimer's disease Formerly held Lapsed on the fee record Ended Mar 16, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 16, 2022 | From the USPTO record |
| US 7,618,975 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof Lapsed on the fee record Ended Nov 17, 2021 · From the USPTO record | Lapsed on the fee record | Ended Nov 17, 2021 | From the USPTO record |
| US 8,309,562 | Compounds and therapeutical use thereof Lapsed on the fee record Ended Nov 13, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 13, 2020 | From the USPTO record |